Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Up 5.4% – Time to Buy?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares rose 5.4% on Friday. The stock traded as high as $64.34 and last traded at $64.79. Approximately 235,189 shares were traded during trading, a decline of 49% from the average session volume of 461,895 shares. The stock had previously closed at $61.45.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. B. Riley Financial raised their price objective on shares of Eton Pharmaceuticals from $70.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Zacks Research downgraded shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 10th. Craig Hallum restated a “buy” rating and issued a $78.00 target price on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. Weiss Ratings raised shares of Eton Pharmaceuticals from a “hold (c)” rating to a “buy (b-)” rating in a research report on Monday, November 9th. Finally, Canaccord Genuity Group raised their price target on shares of Eton Pharmaceuticals from $68.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.75.

Eton Pharmaceuticals Price Performance

The firm has a market capitalization of $1.84 billion, a PE ratio of 42.34 and a beta of 0.89. The business has a 50-day moving average of $55.26 and a 200 day moving average of $37.71. The company has a current ratio of 1.79, a quick ratio of 1.58 and a debt-to-equity ratio of 0.13.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 104.82%. The firm had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million. As a group, research analysts anticipate that Eton Pharmaceuticals, Inc. will post 1.54 EPS for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In related news, insider David Krempa sold 25,000 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the transaction, the insider directly owned 37,025 shares in the company, valued at approximately $2,409,216.75. The trade was a 40.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ipek Erdogan-Trinkaus sold 3,500 shares of the company’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $67.41, for a total transaction of $235,935.00. Following the completion of the sale, the insider directly owned 4,081 shares of the company’s stock, valued at $275,100.21. The trade was a 46.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 82,666 shares of company stock valued at $5,045,607 over the last ninety days. Corporate insiders own 16.49% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Marshall Wace LLP lifted its holdings in Eton Pharmaceuticals by 83.6% during the third quarter. Marshall Wace LLP now owns 457,432 shares of the company’s stock worth $23,553,000 after acquiring an additional 208,250 shares during the period. Steward Partners Investment Advisory LLC bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at $593,000. Voya Investment Management LLC bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at $264,000. Global Retirement Partners LLC purchased a new stake in shares of Eton Pharmaceuticals during the 3rd quarter valued at $26,000. Finally, Morse Asset Management Inc purchased a new stake in shares of Eton Pharmaceuticals during the 3rd quarter valued at $35,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.